In second graph, add Dayton, Ohio (Kettering Medical Center) to list of proton therapy centers.
The corrected release reads:
15% INCREASE IN PROTON THERAPY PAYMENT RATE FOR 2012 RECENTLY APPROVED BY CMS STRENGTHENS THE ECONOMIC CASE FOR PROTON CENTERS UNDER DEVELOPMENT BY AMERICAN SHARED HOSPITAL SERVICES
AMERICAN SHARED HOSPITAL SERVICES (AMEX:AMS)
, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, said today that the recent announcement by the Centers for Medicare & Medicade Services (CMS) of a 15% increase in the payment rate of proton therapy for hospital based centers beginning in 2012 strengthens the economic case for the proton centers now under development by the Company. "We are pleased that CMS recognizes the therapeutic value of proton therapy, now widely regarded as the optimal radiation treatment for an increasing variety of cancers. This payment increase will facilitate the development of much-needed proton therapy centers throughout the country," said AMS Chairman and Chief Executive Officer Ernest A. Bates, M.D.
AMS is developing hospital based proton therapy centers in Dayton, Ohio (Kettering Medical Center), Boston (Tufts Medical Center), Orlando (Orlando Regional Healthcare) and Long Beach, California (Long Beach Memorial Medical Center).
American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st Century® concept. Through its preferred stock investment in Mevion Medical Systems, Inc., formerly Still River Systems, AMS also plans to complement these services with the MEVION S250 proton beam radiation therapy (PBRT) system, which has not yet been approved by the FDA.